189102-18-9

Upstream product

• 64190-52-9 (8S,20S)-de-A,B-20-(hydroxymethyl)pregnan-8-ol 
• 50-14-6 Calciferol 
• 79271-56-0 triethylsilyl trifluoromethyl sulfonate 
• 98-59-9 p-toluenesulfonyl chloride 
• 66774-80-9 (S)-2-((3R,3aR,7S,7aR)-octahydro-7-hydroxy-3a-methyl-1H-inden-3-yl)propyl 4-methylbenzenesulfonate 

Downstream Products

• 1335097-71-6 (20R)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D₃ 
• 1335097-70-5 (20R)-1α-[(tert-butyldimethylsilyl)oxy]-22,22-dimethyl-25-[(triethylsilyl)oxy]-2-methylene-19-norvitamin D(3) tert-butyldimethylsilyl ether 
• 235108-11-9 (8S,20R)-des-A,B-8-[(triethylsilyl)oxy]-20-[(p-toluenesulfonyl)oxy]methyl-pregnane 
• 1335097-63-6 (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D₃ 
• 1335097-62-5 (20S)-1α-[(tert-butyldimethylsilyl)oxy]-22,22-dimethyl-25-[(triethylsilyl)oxy]-2-methylene-19-norvitamin D(3) tert-butyldimethylsilyl ether 
• 189102-63-4 (1S,5S)-3-[2-[(1S,3aS,7aS)-1-{(R)-1-[2-((S)-5,5-Diethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-ethoxy]-ethyl}-7a-methyl-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-5-hydroxymethyl-4-methylene-cyclohexanol 
• 189102-64-5 (1R,5R)-3-[2-[(1S,3aS,7aS)-1-{(R)-1-[2-((S)-5,5-Diethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-ethoxy]-ethyl}-7a-methyl-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-5-hydroxymethyl-4-methylene-cyclohexanol 
• 725229-62-9 1,4-bis-[2-(4-{2-[3,5-bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-propyl]-1H-[1,2,3]triazole 
• 725229-60-7 4-((R)-2-{(1R,3aS,7aR)-4-[2-[3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-propyl)-1-phenyl-1H-[1,2,3]triazole 
• 725229-53-8 4-[(R)-2-((1R,3aR,4S,7aR)-7a-Methyl-4-triethylsilanyloxy-octahydro-inden-1-yl)-propyl]-1-phenyl-1H-[1,2,3]triazole 

Relevant academic research and scientific papers

(20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-HYDROXYVITAMIN D3

Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a varie

DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3

Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a vari

2-Methylene-(17Z)-17(20)-Dehydro-19,21-Dinor-Vitamin D Analogs

This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α, 25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relative

2-Methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses

This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of

Vitamin D analogs for obesity prevention and treatment

Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α

Vitamin D side chain triazole analogs via cycloaddition 'click' chemistry

Cycloaddition of a vitamin D side chain terminal acetylene with phenyl azide and separately with a vitamin D side chain terminal azide produced the corresponding 1,2,3-triazole monomeric and dimeric analogs of 1α-hydroxyvitamin D3 in good yields.

Antiproliferative hybrid analogs of the hormone 1α,25-dihydroxyvitamin D3: Design, synthesis, and preliminary biological evaluation

The combination of 10-12 kbar pressure plus Lewis acidic zinc dichloride promotes highly regioselective and stereoselective Diels-Alder cycloaddition between 3-bromo-2-pyrone, prepared in a new way, and unactivated terminal alkene 4-(tert-butyldimethylsiloxy)-1-butene. The conjugate base of A-ring allylic phosphine oxide 20 adds chemospecifically to the C-8 keto group of some C-8,C-24-diketones to form directly metabolically resistant 24-oxo analogs of 1α,25-dihydroxyvitamin D3 (calcitriol). Several of these new hybrid analogs are as efficacious in vitro as calcitriol at inhibiting growth of murine keratinocytes even at physiologically relevant 10-100 nanomolar concentrations.